PMID- 32979348
OWN - NLM
STAT- MEDLINE
DCOM- 20210924
LR  - 20210924
IS  - 1931-3543 (Electronic)
IS  - 0012-3692 (Linking)
VI  - 159
IP  - 3
DP  - 2021 Mar
TI  - Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced 
      by Mitomycin C.
PG  - 1197-1207
LID - S0012-3692(20)34738-3 [pii]
LID - 10.1016/j.chest.2020.09.238 [doi]
AB  - BACKGROUND: Pulmonary venoocclusive disease (PVOD) is an uncommon form of 
      pulmonary hypertension (PH) predominantly characterized by pulmonary vein and 
      capillary involvement. An association between chemotherapy, in particular 
      mitomycin C (MMC), and PVOD has been reported. RESEARCH QUESTION: What are the 
      characteristics of MMC-induced PVOD, and what is the prognosis for patients with 
      MMC-induced PVOD? STUDY DESIGN AND METHODS: We report the clinical, functional, 
      radiologic, and hemodynamic characteristics at diagnosis and outcomes of patients 
      with PVOD from the French PH Registry after exposure to MMC. The results are 
      expressed as the median (minimum-maximum). RESULTS: From June 2011 to December 
      2018, 17 incident cases of MMC-induced PVOD were identified. At diagnosis, these 
      patients had severe clinical and functional impairment, with 12 patients having a 
      New York Heart Association (NYHA) functional class of III or IV and a 6-min walk 
      distance of 220 (0-465) m. Right heart catheterization confirmed severe 
      precapillary PH with a mean pulmonary artery pressure of 38 (30-52) mm Hg, a 
      cardiac index of 2.2 (1.5-4) L/(min x m(2)), and pulmonary vascular resistance of 
      8.3 (5.1-14.5) Wood units. The diffusing capacity of the lungs for carbon 
      monoxide was markedly decreased at 31% (20%-51%) of the theoretical values 
      associated with severe hypoxemia. MMC was withdrawn for all patients, and 14 
      patients received specific pulmonary arterial hypertension (PAH) therapies. Among 
      these patients, mild but statistically insignificant improvements were observed 
      in NYHA functional class (P = .10), 6-min walk distance (P = .09), and pulmonary 
      vascular resistance (-4.7 Wood units; P = .052) at reassessment (median delay of 
      4.8 months). Three patients experienced pulmonary edema requiring the cessation 
      or reduction of PAH treatment. The median overall survival was 20 months, and the 
      6-, 12-, and 24-month survival rates were 76%, 58%, and 18%, respectively. 
      INTERPRETATION: PVOD after MMC treatment is a rare but life-threatening 
      complication associated with a poor prognosis despite MMC withdrawal and 
      PAH-specific therapy.
CI  - Copyright (c) 2020 American College of Chest Physicians. Published by Elsevier Inc. 
      All rights reserved.
FAU - Certain, Marie-Caroline
AU  - Certain MC
AD  - Department of Respiratory and Intensive Care Medicine, National French Reference 
      Constitutive Center for Rare Pulmonary Diseases, Hopital Francois Mitterrand, 
      Burgundy University Hospital, Dijon, France.
FAU - Chaumais, Marie-Camille
AU  - Chaumais MC
AD  - INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", 
      Hopital Marie Lannelongue, Le Plessis-Robinson, France; Assistance 
      Publique-Hopitaux de Paris (AP-HP), Department of Pharmacy, Hopital Bicetre, Le 
      Kremlin-Bicetre, France; University of Paris-Saclay, Faculty of Pharmacy, 
      Chatenay Malabry, France.
FAU - Jais, Xavier
AU  - Jais X
AD  - INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", 
      Hopital Marie Lannelongue, Le Plessis-Robinson, France; AP-HP, Department of 
      Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral 
      Center, Hopital Bicetre, Le Kremlin-Bicetre, France; University of Paris-Saclay, 
      School of Medicine, Le Kremlin-Bicetre, France.
FAU - Savale, Laurent
AU  - Savale L
AD  - INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", 
      Hopital Marie Lannelongue, Le Plessis-Robinson, France; AP-HP, Department of 
      Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral 
      Center, Hopital Bicetre, Le Kremlin-Bicetre, France; University of Paris-Saclay, 
      School of Medicine, Le Kremlin-Bicetre, France.
FAU - Seferian, Andrei
AU  - Seferian A
AD  - AP-HP, Department of Respiratory and Intensive Care Medicine, Pulmonary 
      Hypertension National Referral Center, Hopital Bicetre, Le Kremlin-Bicetre, 
      France.
FAU - Parent, Florence
AU  - Parent F
AD  - AP-HP, Department of Respiratory and Intensive Care Medicine, Pulmonary 
      Hypertension National Referral Center, Hopital Bicetre, Le Kremlin-Bicetre, 
      France.
FAU - Georges, Marjolaine
AU  - Georges M
AD  - Department of Respiratory and Intensive Care Medicine, National French Reference 
      Constitutive Center for Rare Pulmonary Diseases, Hopital Francois Mitterrand, 
      Burgundy University Hospital, Dijon, France; University of Bourgogne 
      Franche-Comte, School of Medicine, Dijon, France; INSERM UMR 123-1, LNC Faculty 
      of Medicine and Pharmacy, Dijon, France.
FAU - Favrolt, Nicolas
AU  - Favrolt N
AD  - Department of Respiratory and Intensive Care Medicine, National French Reference 
      Constitutive Center for Rare Pulmonary Diseases, Hopital Francois Mitterrand, 
      Burgundy University Hospital, Dijon, France.
FAU - Bourdin, Arnaud
AU  - Bourdin A
AD  - Department of Respiratory Diseases, Hopital Arnaud de Villeneuve, Montpellier 
      University Hospitals, Montpellier, France; University of Montpellier, School of 
      Medicine, Montpellier, France; INSERM U1046, Montpellier, France.
FAU - Boissin, Clement
AU  - Boissin C
AD  - Department of Respiratory Diseases, Hopital Arnaud de Villeneuve, Montpellier 
      University Hospitals, Montpellier, France.
FAU - Cottin, Vincent
AU  - Cottin V
AD  - Department of Respiratory Medicine, National Coordinating Reference Center for 
      Rare Pulmonary Diseases, Hopital Louis Pradel, Lyon, France; Claude-Bernard Lyon 
      1 University, University of Lyon, INRA, UMR754, Lyon, France; UMR 754, Lyon, 
      France.
FAU - Traclet, Julie
AU  - Traclet J
AD  - Department of Respiratory Medicine, National Coordinating Reference Center for 
      Rare Pulmonary Diseases, Hopital Louis Pradel, Lyon, France.
FAU - Renard, Sebastien
AU  - Renard S
AD  - Department of Cardiology, Assistance Publique-Hopitaux de Marseille (AP-HM), 
      Hopital de la Timone, Aix-Marseille University, Marseille, France.
FAU - Noel, Violaine
AU  - Noel V
AD  - Internal Medicine Department, Hopital Robert-Debre, Reims, France.
FAU - Picard, Francois
AU  - Picard F
AD  - Department of Cardiology, University Hospital of Bordeaux, Bordeaux, France.
FAU - Girerd, Barbara
AU  - Girerd B
AD  - INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", 
      Hopital Marie Lannelongue, Le Plessis-Robinson, France; AP-HP, Department of 
      Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral 
      Center, Hopital Bicetre, Le Kremlin-Bicetre, France; University of Paris-Saclay, 
      School of Medicine, Le Kremlin-Bicetre, France.
FAU - Ghigna, Maria-Rosa
AU  - Ghigna MR
AD  - Department of Pathology, Hopital Marie Lannelongue, Le Plessis-Robinson, France.
FAU - Perros, Frederic
AU  - Perros F
AD  - INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", 
      Hopital Marie Lannelongue, Le Plessis-Robinson, France.
FAU - Sitbon, Olivier
AU  - Sitbon O
AD  - INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", 
      Hopital Marie Lannelongue, Le Plessis-Robinson, France; AP-HP, Department of 
      Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral 
      Center, Hopital Bicetre, Le Kremlin-Bicetre, France; University of Paris-Saclay, 
      School of Medicine, Le Kremlin-Bicetre, France.
FAU - Bonniaud, Philippe
AU  - Bonniaud P
AD  - Department of Respiratory and Intensive Care Medicine, National French Reference 
      Constitutive Center for Rare Pulmonary Diseases, Hopital Francois Mitterrand, 
      Burgundy University Hospital, Dijon, France; University of Bourgogne 
      Franche-Comte, School of Medicine, Dijon, France; INSERM UMR 123-1, LNC Faculty 
      of Medicine and Pharmacy, Dijon, France.
FAU - Humbert, Marc
AU  - Humbert M
AD  - INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", 
      Hopital Marie Lannelongue, Le Plessis-Robinson, France; AP-HP, Department of 
      Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral 
      Center, Hopital Bicetre, Le Kremlin-Bicetre, France; University of Paris-Saclay, 
      School of Medicine, Le Kremlin-Bicetre, France.
FAU - Montani, David
AU  - Montani D
AD  - INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", 
      Hopital Marie Lannelongue, Le Plessis-Robinson, France; AP-HP, Department of 
      Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral 
      Center, Hopital Bicetre, Le Kremlin-Bicetre, France; University of Paris-Saclay, 
      School of Medicine, Le Kremlin-Bicetre, France. Electronic address: 
      david.montani@aphp.fr.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200924
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 50SG953SK6 (Mitomycin)
SB  - IM
CIN - Chest. 2021 Mar;159(3):910-911. PMID: 33678275
MH  - Antibiotics, Antineoplastic/administration & dosage/adverse effects
MH  - Cardiac Catheterization/methods/statistics & numerical data
MH  - Female
MH  - France/epidemiology
MH  - Functional Status
MH  - Humans
MH  - *Hypertension, Pulmonary/diagnosis/etiology/physiopathology
MH  - *Lung/blood supply/diagnostic imaging
MH  - Male
MH  - Middle Aged
MH  - *Mitomycin/administration & dosage/adverse effects
MH  - Patient Care Management/methods
MH  - Pharmacovigilance
MH  - Prognosis
MH  - Pulmonary Circulation/drug effects
MH  - *Pulmonary Veno-Occlusive Disease/chemically 
      induced/diagnosis/mortality/physiopathology
MH  - Pulmonary Wedge Pressure
MH  - Registries/statistics & numerical data
MH  - Survival Analysis
MH  - Withholding Treatment
OTO - NOTNLM
OT  - mitomycin C
OT  - pharmacovigilance
OT  - pulmonary hypertension
OT  - pulmonary venoocclusive disease
EDAT- 2020/09/27 06:00
MHDA- 2021/09/25 06:00
CRDT- 2020/09/26 20:08
PHST- 2020/05/19 00:00 [received]
PHST- 2020/08/05 00:00 [revised]
PHST- 2020/09/16 00:00 [accepted]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2021/09/25 06:00 [medline]
PHST- 2020/09/26 20:08 [entrez]
AID - S0012-3692(20)34738-3 [pii]
AID - 10.1016/j.chest.2020.09.238 [doi]
PST - ppublish
SO  - Chest. 2021 Mar;159(3):1197-1207. doi: 10.1016/j.chest.2020.09.238. Epub 2020 Sep 
      24.